

6-25-03

\$1636

AMENDMENT TRANSMITTAL LETTER (Large Entity)			Docket No. RDID0073US		
Applicant(s): Mueller, Rainer, et al.					
Serial No. 09/911,132	Filing Date July 23, 2001	Examiner Maria B. Marvich, Ph.D.		Group Art Unit 1636	
Invention: EXPRESSION OF ALKALINE PHOSPHATASE IN YEAST					
<div><div></div><div><u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u></div><div>Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.</div><div> 23690 PATENT TRADEMARK OFFICE</div></div>					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	10 -	20 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	5 -	8 =	0 x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<div><div><input type="checkbox"/> No additional fee is required for amendment.</div><div><input checked="" type="checkbox"/> Please charge Deposit Account No. 02-2958 in the amount of A duplicate copy of this sheet is enclosed.</div><div><input type="checkbox"/> A check in the amount of to cover the filing fee is enclosed.</div><div><input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 02-2958. A duplicate copy of this sheet is enclosed.<div><input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.</div><div><input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</div></div></div>					
<div> Signature</div>			Dated: June 24, 2003		
Kenneth J. Waite, Reg. No. 45,189 Roche Diagnostic Corporation 9115 Hague Road, Bldg. D Indianapolis, IN 46250-0457 Telephone No.: (317) 521-3104 Facsimile No.: (317) 521-2883			<div><div>I certify that this document and fee is being deposited on with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.</div><div>Signature of Person Mailing Correspondence</div><div>Typed or Printed Name of Person Mailing Correspondence</div></div>		
cc: Via Express Mail Label No. EL566557760US					

RECEIVED

JUN 30 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Mueller, Rainer, et al.

Docket No.

RDID0073US

Serial No.

09/911,132

Filing Date

July 23, 2001

Examiner

Maria B. Marvich, Ph.D.

Group Art Unit

1636

Invention: EXPRESSION OF ALKALINE PHOSPHATASE IN YEAST

RECEIVED

JUN 30 2003

TECH CENTER 1600/2900

I hereby certify that this

Response and Amendment*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under

37 CFR 1.10 in an envelope addressed to: ~~The Assistant Commissioner for Patents, Washington, D.C. 20234~~ onJune 24, 2003.*(Date)*

PO BOX 1450

ALEXANDRIA, VA 22313-1450

EL566557760US*(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)***Janine Schumm***("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**



Docket No. RDID 0073 US

PATENT

#17/C
Hita
7/2/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mueller, Rainer, *et al.*

RECEIVED

Application No.: 09/911,132

Group No.: 1636

JUN 30 2003

Filed: July 23, 2001

Examiner: Maria B. Marvich, PhD

TECH CENTER 1600/2900

For: EXPRESSION OF ALKALINE PHOSPHATASE IN YEAST

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE AND AMENDMENT

Please enter the following amendments and new claims in response to the Office Action mailed December 24, 2002. A Petition for Extension of Time for a three month extension is filed contemporaneously.

IN THE SPECIFICATION:

Please enter the substitute abstract that is attached hereto. The Examiner requested a substitute specification under 37 CFR 1.52(a) and (b). Applicants assume that an entire new copy of the specification is not needed, but rather an amended version of the Abstract will suffice. The undersigned Attorney for the Applicants hereby states that the substitute abstract contains no new matter.

IN THE CLAIMS:

Please cancel claims 1 through 5 and 8 through 15. Please enter new claims 16 through 23 as shown on the attached sheets.

REMARKS

New claim 16 is similar to previous claim 1, but is being submitted as a new claim to make it simpler to read the claim as submitted. In the Office Action, the Examiner rejected claim 1 and dependent claims because of the phrases "utilized" and "are used" were present without